On January 17, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, held its 2024 Annual Meeting of Shareholders, where several key proposals were voted upon. The meeting saw the election of Class I and Class II directors, with Brian Szymczak, Bruce Bent, Mark Hilz, and David R. Wells securing their positions. Shareholders approved the full issuance of shares pursuant to an agreement with Lincoln Park Capital Fund, LLC, the 2023 Employee Stock Purchase Plan, and the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024. Additionally, an amendment to effect a reverse stock split and a change of the corporate name to 'HeartSciences Inc.' were approved. However, the proposal to decrease the number of...Show More

On January 17, 2024, Heart Test Laboratories, Inc., also known as HeartSciences, held its 2024 Annual Meeting of Shareholders, where several key proposals were voted upon. The meeting saw the election of Class I and Class II directors, with Brian Szymczak, Bruce Bent, Mark Hilz, and David R. Wells securing their positions. Shareholders approved the full issuance of shares pursuant to an agreement with Lincoln Park Capital Fund, LLC, the 2023 Employee Stock Purchase Plan, and the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024. Additionally, an amendment to effect a reverse stock split and a change of the corporate name to 'HeartSciences Inc.' were approved. However, the proposal to decrease the number of shares required for a quorum did not receive sufficient votes, leading to an adjournment to solicit additional votes. The reconvened meeting is scheduled for February 15, 2024, and will be accessible via live webcast. The record date for the Annual Meeting was November 20, 2023, and shareholders who have already voted do not need to recast their votes unless they wish to change their decision on the quorum proposal.